After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that BioXcel Therapeutics Announces $25 Million Registered Direct Offering.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
BioXcel Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $2.85 and fluctuated between $2.9600 as its day high and $2.6000 as its day low. The current market capitalization of BioXcel Therapeutics Inc is $86.58M. A total of 1.21 million shares were traded on the day, compared to an average of 1.59M shares.
In the most recent transaction, Mehta Vimal sold 30,000 shares of BTAI for 20.18 per share on Jun 16 ’23. After the transaction, the CEO and President now owns 39,903 company shares. In a previous transaction on Jun 15 ’23, Mehta Vimal sold 30,000 shares at 21.54 per share. BTAI shares that CEO and President owns now total 39,903.
Among the insiders who sold shares, Mehta Vimal disposed of 6,500 shares on May 22 ’23 at a per-share price of $25.79. This resulted in the CEO and President holding 37,294 shares of BTAI after the transaction. In another insider transaction, Steinhart Richard I sold 5,000 shares at $27.17 per share on May 15 ’23. Company shares held by the Chief Financial Officer now total 1,500.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, BTAI has a high of $29.56 and a low of $1.91.
As of this writing, BTAI has an earnings estimate of -$0.78 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.65 per share and a lower estimate of -$0.93. The company reported an EPS of -$1.72 in the last quarter, which was -32.30% lower than expectations of -$1.3.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BTAI’s latest balance sheet shows that the firm has $232.97M in Cash & Short Term Investments as of fiscal 2021. There were $1.10M in debt and $16.67M in liabilities at the time. Its Book Value Per Share was -$1.89, while its Total Shareholder’s Equity was $221.67M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BTAI is Buy with a score of 3.75.
